-
Mashup Score: 1Careers - 1 year(s) ago
Revolutionary technologies such as CRISPR/Cas9 only emerge a few times in one’s life. Join our team and help us pioneer transformative, gene-based medicines We are building a world-class research and development center with outstanding people who want to make a difference. We’re moving at a rapid pace, and every day presents new excitements and challenges. We rely on each other to tackle…
Source: CRISPRCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 10CRISPR Therapeutics - Allogeneic Cell Therapies - 1 year(s) ago
We continue our conversation with CRISPR Therapeutics in this second in our three-part series. Listen in as the Cutaneous Lymphoma Foundation’s CEO Susan Tho…
Source: YouTubeCategories: Future of Medicine, Latest HeadlinesTweet-
Susan Thornton, CEO of Cutaneous Lymphoma Foundation, and @CRISPRTX's Chief Medical Officer, Dr. Phuong Khanh (PK) Morrow, recently discussed CAR T therapy in a CLF #IndustrySpotlight. View the video here to learn more: https://t.co/nyoRZYBjrp.
-
-
Mashup Score: 10CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results | CRISPR Therapeutics - 1 year(s) ago
-Regulatory submissions complete for exagamglogene autotemcel (exa-cel) in Europe for transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD); U.S. rolling Biologics Licensing Application (BLA) submission on track for completion by end of Q1 2023- -Enrollment and dosing ongoing
Source: CRISPR TherapeuticsCategories: Future of Medicine, Latest HeadlinesTweet-
Today, we announced our fourth quarter and full year earnings results. Read more about our recent highlights and outlook: https://t.co/4o5TeANGCS https://t.co/dh0aihNmGE
-
-
Mashup Score: 9Careers - 1 year(s) ago
Revolutionary technologies such as CRISPR/Cas9 only emerge a few times in one’s life. Join our team and help us pioneer transformative, gene-based medicines We are building a world-class research and development center with outstanding people who want to make a difference. We’re moving at a rapid pace, and every day presents new excitements and challenges. We rely on each other to tackle…
Source: CRISPRCategories: Future of Medicine, Latest HeadlinesTweet-
CRISPR Therapeutics’ lipid nanoparticles (LNP) team aims to transform how CRISPR components are delivered with nonviral methods. To join our diverse, driven, and growing LNP team, visit: https://t.co/CeNHglR7eA https://t.co/CNkrnd3Kxo
-
-
Mashup Score: 2StackPath - 1 year(s) ago
www.worldcancerday.org is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation is complete. Reference ID IP Address Date and Time 93b3dba503c820aa98468c3065749fe2 18.220.203.119 02/04/2023 03:09 PM UTC Protected by StackPath
Source: www.worldcancerday.orgCategories: Future of Medicine, Latest HeadlinesTweet-
#WorldCancerDay brings a global focus on efforts to #CloseTheCareGap and increase access to equitable cancer care around the world. Learn more about this initiative here: https://t.co/B10uFtVB3M https://t.co/OKmxlTDas3
-
-
Mashup Score: 2Chuck - Renal Cell Carcinoma - 1 year(s) ago
Facing an Unexpected Challenge Renal Cell Carcinoma Chuck’s Story Chuck is a self-professed type A personality. An ‘Irish Catholic kid from Boston,’ he reached the top of the corporate ladder in a demanding position as Vice President of Business Operations with the National Fire Protection Association. Naturally, he…
Source: CRISPRCategories: Future of Medicine, Latest HeadlinesTweet-
Meet Chuck, a Boston native and incredible advocate living with #renalcellcarcinoma. Read his inspiring story here: https://t.co/XBR2pOWlNp #kidneycancers https://t.co/Oy96iSpnQ4
-
-
Mashup Score: 4CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development | CRISPR Therapeutics - 1 year(s) ago
ZUG, Switzerland and BOSTON , Dec. 19, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Alex Harding , M.D., M.B.A., as Senior Vice President and
Source: CRISPR TherapeuticsCategories: Future of Medicine, Latest HeadlinesTweet-
We’re pleased to announce that Alex Harding, M.D., M.B.A., is joining us as Senior Vice President and Head of Business Development. Read more about his appointment here: https://t.co/KpL09GwFxQ https://t.co/EcacBd2dpv
-
-
Mashup Score: 9CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON™ Trial of CTX110® | CRISPR Therapeutics - 1 year(s) ago
-Update provided for both Part A (single dose with optional re-dosing) and Part B (consolidation dosing) of the Phase 1 CARBON™ clinical trial- -Part A data presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition confirm that CTX110 ® can lead to long-term durable
Source: CRISPR TherapeuticsCategories: Future of Medicine, Latest HeadlinesTweet-
We're pleased to provide an update for both Part A and Part B of our ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX110®, our wholly-owned allogeneic CAR T cell therapy targeting CD19+ B-cell malignancies. Learn more: https://t.co/efXHM2WuqP #ASH22 https://t.co/USPaVh4vm9
-
-
Mashup Score: 6CRISPR Therapeutics and Vertex to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition | CRISPR Therapeutics - 1 year(s) ago
– Oral presentation of encore clinical data from Phase 3 clinical trials of exa-cel – – Oral and poster presentations on quality-of-life impacts of sickle cell disease or transfusion-dependent beta-thalassemia and burden of hematopoietic stem cell transplant – BOSTON and ZUG, Switzerland
Source: CRISPR TherapeuticsCategories: Future of Medicine, Latest HeadlinesTweet-
We are pleased to announce an oral, encore presentation of clinical data from patients with sickle cell disease or beta thalassemia treated with the investigational therapy exa-cel at the @ASH_hematology Annual Meeting. Learn more: https://t.co/YuCGl8uWNg https://t.co/yMBE7syRuf
-
-
Mashup Score: 1The Future of Cancer Care Forum: Advancing Cancer Research, Innovation and Health Equity - 1 year(s) ago
Regi
Categories: Future of Medicine, Latest HeadlinesTweet-
@CRISPRTX's Chief Medical Officer, P.K. Morrow, will be participating in the @ACSCAN Future of Cancer Care Forum on Dec. 2, 2022. Participants at this event will discuss ways to increase access to innovative and equitable cancer treatments. More info here: https://t.co/JBKQ2hjqmH https://t.co/ZyJHpSKYtd
-
Brigid McEwan, a program manager for in vivo programs at CRISPR Therapeutics, believes in innovation that brings science to patients by working toward advancing meaningful medicines. Learn more here: https://t.co/15Vy5LnM5u #CRISPRTX https://t.co/upoAUDnRnr